UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Relay Therapeutics, Inc. (the “Company”) will be conducting meetings with participants attending the 40th Annual J.P. Morgan Healthcare Conference (the “Conference”) during the week of January 10, 2022. A copy of the slides to be presented by the Company at the Conference is furnished as Exhibit 99.1 to this Current Report on Form 8-K, which is incorporated herein by reference.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Exhibits.
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
RELAY THERAPEUTICS, INC. |
|
|
|
|
Date: |
January 10, 2022 |
By: |
/s/ Brian Adams |
|
|
|
Brian Adams, J.D. |
40th Annual J.P. Morgan Healthcare Conference Company Presentation January 2022 Exhibit 99.1
Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as ‘‘aim,’’ ‘‘anticipate,’’ ‘‘assume,’’ ‘‘believe,’’ ‘‘contemplate,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘design,’’ ‘‘due,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘goal,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘objective,’’ “opportunity,” ‘‘plan,’’ ‘‘predict,’’ ‘‘positioned,’’ ‘‘potential,’’ ‘‘seek,’’ ‘‘should,’’ ‘‘target,’’ ‘‘will,’’ ‘‘would’’ and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include express or implied statements about the initiation, timing, progress and results of our current and future clinical trials and current and future preclinical studies of our product candidates; the timing of disclosures regarding our pipeline and additional clinical data for RLY-4008; the potential therapeutic benefits of our product candidates, including potential efficacy and tolerability, and combination potential of our product candidates; whether preliminary results from our preclinical or clinical trials will be predictive of the final results of the trials or any future clinical trials of our product candidates; the possibility that unconfirmed results from these trials will not be confirmed by additional data as the clinical trials progress; the competitive landscape and market opportunities for our product candidates; the expected strategic benefits under our collaborations; our ability to successfully establish or maintain collaborations or strategic relationships for our product candidates; expectations regarding current and future interactions with the U.S. Food and Drug Administration (FDA); our ability to manufacture our product candidates in conformity with the FDA’s requirements; the capabilities and development of our DynamoTM platform; our financial performance; the effect of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and future clinical trials; our plans to develop, manufacture and commercialize our current product candidates and any future product candidates; and the implementation of our business model and strategic plans for our business, current product candidates and any future product candidates. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make due to a number of risks and uncertainties. These and other risks, uncertainties and important factors are described in the section entitled "Risk Factors" in our most recent Annual Report on Form 10-K or most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent our views only as of the date of this presentation and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.
Relay Tx – Patient-Driven, Growth-Oriented Clear Focus Validated Targets Therapeutic Areas Modalities Small molecules Oncology Genetic diseases Challengers Innovators New Breed of Biotech EXPERIMENTATION COMPUTATION Validated Approach PI3KαPAN RLY-2608 FGFR2 RLY-4008 SHP2 RLY-1971 The more we do, the better we get Execution-Focused
Relay Tx – Created by the Nexus of 3 Unstoppable Forces and Data INTEGRATION Improving Experimental insight Increasing Genomic data 1990 Increasing Computational power Data Data Data Increasing efficiency and effectiveness of drug discovery Motion-Based Drug Design™
The Dynamo™ Platform – Integrating Experimentation with Computation Chemical biology insights Deep structural understanding Physics-based simulations AI / ML Dynamo™️ Platform EXPERIMENTATION COMPUTATION NMR and HDX-MS Data-constrained molecular dynamics Cryo-EM Ambient temp. X-Ray crystallography Integrated structural biophysics Bespoke DNA encoded libraries Target mechanistics Target mutational landscape analyses Integrated pharmacology DMPK model data Long time- scale MD Free energy calculations Digitally encoded libraries Swimming simulations Differential dynamics AlphaFold 2 Generative design Active learning ADME/PK models ML-DEL
The Dynamo™ Platform – Experimentation EXPERIMENTATION Chemical biology insights Deep structural understanding Tools Cryo-EM Ambient Temp X-Ray Crystallo-graphy People and Functions Target Mechanistics Nanoscale Chemistry Time-resolved Biophysics Protein Engineering Etc. Experience 2016 Today 3 clinical assets in 5 years
The Dynamo™ Platform – Computation COMPUTATION Physics-based simulations AI / ML Tools Swimming Simulations Virtual Screens Experience 2016 Today 3 clinical assets in 5 years People and Functions Automated Chemical Design Force Field Development Quantum Mechanics Free Energy Methods Etc.
The Dynamo™ Platform – The Power of Experimentation + Computation Chemical biology insights Deep structural understanding Physics-based simulations AI / ML Dynamo™️ Platform EXPERIMENTATION COMPUTATION 5+ earlier stage programs in pipeline 2 therapeutic areas The more we do, the better we get 3 clinical assets PI3KαPAN RLY-2608 FGFR2 RLY-4008 SHP2 RLY-1971
Chemical biology insights Deep structural understanding Physics-based simulations AI / ML Dynamo™️ Platform EXPERIMENTATION COMPUTATION Relay Tx – Our 3-Step Drug Discovery Process Long Time Scale MD Examples of tools used: Examples of tools used: FEP Simulation ML-DEL Screen Virtual Screens Understand how to drug the protein Identify a chemical starting point Optimize until development candidate selected Elucidate novel disease biology Develop and commercialize 2 3 1 ML ADME Models Structural Biophysics
z Relay Tx – Our Current Focus Current Focus Modalities Therapeutic Areas Small molecules Oncology Genetic diseases SHP2 FGFR2 Validated Targets Challenger programs Innovator programs PI3Kα -- Rapid path to clinical POC Clear patient selection strategy Amenable to Relay Tx’s Dynamo™️ platform Increasing Technical Difficulty Increasing Competition Innovators Challengers Fusion Mutation Amplification Target is a driver of disease Source: Image adapted from Babina IS, Turner NC. Nat Rev Cancer 2017;17: 318-332
Relay Tx – We Have Validated Our Approach and Built Significant Advantage PI3KαPAN RLY-2608 Motion-Based Hypothesis Pre-Clinical Validation Clinical Progress The more we do, the better we get SHP2 RLY-1971 Opportunity Size Annual US patient # Note: Patient #’s refer to total annual number of US patients with late-line cancers compared to comprehensive annual incidence that may be amenable to treatment with our programs *SHP2 combo only includes KRAS G12C in lung and CRC, EGFR mutations in lung, and ALK fusions in lung FGFR2 RLY-4008 * * * # First patient dosed 50-156K H1047X, E542X, E545X 8-20K Fusions, Amps, Muts 38-70K Combo*
Innovators FGFR2 RLY-4008 Mutant + WT 8-20K PI3Kα franchise PI3KαPAN RLY-26081 RLY-2608 Pan-mutant allosteric inhibitor 50-156K PI3KαSPECIFIC H1047R-specific RLY-1047R H1047R allosteric inhibitor 15-48K PI3KαOTHER Additional Other novel mutant selective mechanisms To be announced Other oncology 3 programs To be announced Genetic diseases 2 programs To be announced Challengers SHP2 RLY-1971 38-70K2 --- --- To be announced Relay Tx – Our Extensive Precision Medicines Pipeline Note: Patient #’s refer to total annual number of US patients with late-line cancers compared to comprehensive annual incidence that may be amenable to treatment with our programs 1. RLY-2608 covers H1047X, E542X, E545X hot spots; 2. SHP2 combo only includes KRAS G12C in lung and CRC, EGFR mutations in lung, and ALK fusions in lung Target Program Annual US patient # Preclinical Early Clinical Late Clinical
Relay Tx – What to Expect Execution focus underpins value creation RLY-2608 (PI3KαPAN) RLY-4008 (FGFR2) To be disclosed in 1H 2022 Next target in pipeline RLY-1971 (SHP2) $617M Cash, cash equivalents and investments as of the end of Q3 2021 $381M Net proceeds from follow-on offering in October 2021 Expansion cohorts open Additional data update expected in 2H 2022 Clinical trial initiated GDC-6036 (KRAS G12C) combo trial initiated in July 2021
The Dynamo™ Platform – Evolving with Landscape of Leading Edge Techniques Automated chemical design Protein structure prediction (AlphaFold) ML directed free energy calculations Active learning Long-time scale MD Quantitative DEL Generating data to build pharmacokinetic ML models High-throughput and automated chemistry Structural biology on difficult targets Dynamo™️ Platform EXPERIMENTATION COMPUTATION
Relay Tx Programs
FGFR2 – Highlights from RLY-4008 Interim Clinical Data Disclosure (Oct 2021) Robust inhibition of FGFR2 with promising initial tolerability data Safety and Tolerability Early evidence of tumor regressions across several tumor and alteration types (with 3 out of 6 fusion positive cholangiocarcinoma FGFR-inhibitor naïve patients exhibiting confirmed PRs) Early Efficacy No significant hyperphosphatemia (FGFR1) or diarrhea (FGFR4) observed to-date Selectivity RLY-4008 Data Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference Preliminary data as of 09-Sept-2021 Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021)
FGFR2 – Validated Target Present in Several Tumor Types Fusions Amplifications Mutations FGFR2 Annual Cases (US, comprehensive) FGFR2-altered cancers remain a high unmet medical need Pancreatic Breast Endometrial Skin Melanoma Stomach Lung Bladder CUP Ovarian ~5K-15K patients in the US per year1 ~3K-5K patients in the US per year1 FGFR2 alterations are observed across multiple tumor types2 Three classes of driver alterations in FGFR2 Sources: Image adapted from Babina IS, Turner NC. Nat Rev Cancer 2017;17: 318-332; FoundationInsights® database, using 8 copies as the threshold for amplification, and including only mutations with known or likely functional significance; SEER and ACS databases 1. Patient #’s refer to total annual number of US patients with late-line cancers vs. comprehensive annual incidence that may be amenable to treatment with our programs; 2. Cholangio, cholangiocarcinoma; CUP, carcinoma unknown primary Cholangio Current FDA Accelerated Approvals for FGFR2-Altered Cancers Tumor Type FGFR2 Fusion & Rearrangement FGFR2 Oncogenic Mutation FGFR2 Amplification FGFRi-naïve Cholangio-carcinoma 23-36% ORR Pemigatinib Infigratinib FGFRi-resistant Cholangio-carcinoma Other FGFR2-altered solid tumors No FDA-approved targeted therapy
FGFR2 – Selective Inhibitor Required to Address Large Unmet Medical Need A selective inhibitor of FGFR2 with broad activity against acquired resistance mutations is necessary to address significant unmet need in patients with FGFR2-altered tumors Compound Company Stage FGFR2 Selective Response Rate Dosing Schedule % of Patients with Hyperphosphatemia1 % of Patients with Diarrhea % of Patients Discontinued or Dose Reduced Pemigatinib Approved3 No 36% (ICC) 2 weeks on, 1 week off 94% 47% 23% Infigratinib Approved3 No 23% (ICC) 3 weeks on, 1 week off 90% 24% 75% Futibatinib Phase 2/3 No 42% (ICC) Once daily dosing 91% ~28% 56% Erdafitinib Approved3 No 32% (Urothelial Carcinoma) Personalized dosing based on phosphate levels2 76% 47% 66% High toxicity limits efficacy of non-selective FGFR inhibitors Sources: Pemigatinib – Prescribing information; Infigratinib – Prescribing information; Futibatinib/TAS-120 – AACR 2021 (diarrhea %s approximated from presentation); Erdafitinib – Prescribing information; FOLFOX – ABC-06 Publication in Lancet Oncology 2021 1 As defined by increased serum phosphate; except for infigratinib which is not specified 2 Initial dose (8 mg QD) adjusted to 9 mg QD only in absence of hyperphosphatemia 3 Currently have accelerated approval Second Line: FGFRi Treatment Naïve Precedent Late-Line: Retreating with Chemo Precedent Regimen Trial Stage Population Response Rate Progression-Free Survival (median) Overall Survival (median) % Deaths Due to Chemo % of Patients Discontinued or Dose Reduced FOLFOX Chemotherapy ABC-06 Phase 3 All Comers, 2L 3% (ICC) 3.3 months (ICC) 5.7 months (ICC) 4% 74% Late-line treatment with chemotherapy is highly toxic and only results in incremental efficacy Late-line treatment with chemotherapy can be highly toxic and only results in incremental efficacy FGFRi treatment naïve patient population
FGFR2 – Standard Approach to Discovery Has Had Limited Success Standard Approach FGFR1 FGFR2
FGFR2 – Increasing Experimental Resolution Reveals New Opportunities FGFR1 FGFR2 Down Up Down Up Down Up Down Up Down Up Up Up Down Down Down Up Exploiting the dynamic difference between FGFR1 and FGFR2 enabled Relay Tx to design a selective FGFR2 inhibitor We predicted that a segment of FGFR1 would be fully extended outwards more frequently than the same segment in FGFR2
FGFR2 – RLY-4008 Is Potentially the First Highly Selective and Irreversible FGFR2 Inhibitor Pan-FGFR Inhibitors RLY-4008 AZD4547 Erdafitinib Pemigatinib Futibatinib FGFR2 Note: Single experiment that tested each compound run at 500nM against 468 targets in the absence of ATP and without preincubation Source: KINOMEscanTM by Eurofins DiscoverX FGFR1 FGFR2 FGFR3 FGFR4 Percent Control Percent Control
FGFR2 – RLY-4008 First-in-Human (FIH) Study Design Orally dosed; BID and QD schedules explored using the Bayesian Optimal Interval Escalation (BOIN) design; Starting dose was 50 mg BID Key Objectives: MTD/RP2D, safety, pharmacokinetics, biomarkers (ctDNA, tumor markers), preliminary anti-tumor activity MTD, maximum tolerated dose; RP2D: recommended phase 2 dose. Unresectable or metastatic solid tumors FGFR2-alterations per local assessment (tumor tissue or blood) Both FGFRi-naïve & FGFRi-treated allowed Part 1: Dose Escalation – Enrolling RP2D Part 2: Dose Expansion – Opened December 2021 FGFR2-fusion+ intrahepatic cholangiocarcinoma with prior FGFRi FGFR2-fusion+, non intrahepatic cholangiocarcinoma with/without prior FGFRi FGFR2-amplified, advanced solid tumors with/without prior FGFRi FGFR2-mutant, advanced solid tumors with/without prior FGFRi FGFR2-fusion+ intrahepatic cholangiocarcinoma without prior FGFRi First patient treated in Sept 2020 49 patients recruited over first ~1 year (as of October 2021) excellent execution to-date
FGFR2 – RLY-4008 FIH Study: Parallel Bayesian Dose Optimization Ongoing Preliminary data as of 09-Sept-2021 Dose reductions 2020 2021 SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP Dose cohort enrollment periods – Bayesian dose optimization with enrichment (ongoing) DLT rate Deprioritized 6/7 (86%) 2/7 (29%) 50 BID 3/3 (100%) 2/3 (67%) 100 BID 2/3 (67%) 1/3 (33%) 30 BID 1/4 (25%) 0/4 (0%) 20 BID RLY-4008 QD dose optimization continues 1/7 (14%) 0/7 (0%) 70 QD 4/11 (36%) 1/11 (9%) 50 QD 0/4 (0%) 0/4 (0%) 30 QD 0/5 (0%) 0/5 (0%) 20 QD 0/5 (0%) 0/5 (0%) 40 QD Enrollment ongoing Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021)
Presumed FGFR2- related AEs Off-target AEs Other AEs FGFR2 – RLY-4008 FIH Study: RLY-4008 QD Safety Profile Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference (QD schedule n=32); Bemarituzumab ASCO 2021 Presentation – notes corneal AEs are defined by Standardised MedDRA Queries (SMQ) of corneal disorders, which includes dry eye *Included if ≥ 20% based on both QD (n=32) and BID (n=17) schedules. **Included preferred terms of nail disorder, nail discoloration, nail ridging, onychalgia, onychoclasis, onycholysis, onychomadesis, paronychia. ***Included preferred terms of retinal pigment epithelium detachment, retinopathy, blurred vision, subretinal fluid. Preliminary data as of 09-Sept-2021 Treatment-Emergent Adverse Events* RLY-4008 QD dosing Dry eye: 9% all grades, 0% grade 3+ Corneal AEs: 13% all grades, 0% grade 3+ Bemarituzumab (Phase 2) Dry eye: 26% all grades, 3% grade 3+ Corneal AEs: 67% all grades, 24% grade 3+ Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021) On-target AEs have been mostly low grade (no Gr 4/5, < 10% in the QD dosing regimen), and all of them have been reversible, manageable with dose modification or no intervention and monitorable 3% 0% Hyperphosphatemia 0% 3% Diarrhea 16% Grade 1-2 Grade 3 Dry Eye and Corneal Details * * Key Off-Target Safety (FGFR1 and FGFR 4)
FGFR2 – RLY-4008 FIH Study: RLY-4008 Induced Radiographic Tumor Regression in FGFR Inhibitor-Naïve FGFR2-Fusion+ Cholangiocarcinoma Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference *Confirmed PR; #Tumor resection after data cut off. FGFRi, fibroblast growth factor receptor inhibitor PR, partial response. Preliminary data as of 09-Sept-2021 Best RECIST change from baseline 3/6 patients exhibit a confirmed PR 3/6 patients ongoing on treatment, and 1 patient had resection with curative intent Relative change from baseline in tumor size Pan-FGFR benchmark in this population is 23-36% ORR * * * # 70 QD Resection 50 QD 30 QD ## Most Recent Dose 50 QD Doses 100 BID 50 BID 70 QD 50 QD 30 QD 70 QD 30 QD Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021) 30 QD (ongoing) Dose reduced patient with deepening response over time Doses 100 BID 50 BID 70 QD 50 QD 30 QD
FGFR2 – RLY-4008 FIH Study: RLY-4008 Exhibited Activity in Pan-FGFR Inhibitor Resistant FGFR2-Fusion Cholangiocarcinoma Regardless of FGFR2 Resistance Mutations Preliminary data as of 09-Sept-2021 Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference Note: (N550, N549), (V565, V564), (E566, E565), (L618, L617) are different terminology for the same mutated site; ctDNA, circulating DNA; FGFRi, fibroblast growth factor receptor inhibitor Testing pending No resistance mutation at baseline Resistance mutation not cleared at C2D1 Resistance mutation cleared at C2D1 Clearance of resistance clones implies greater duration in earlier line patients 13/21 (62%) patients with tumor reduction > 10% 7/10 (70%) patients with FGFR2 resistance mutations at baseline had all identified resistance mutations rendered undetectable at C2D1 No resistance mutation detected at baseline Testing pending N550 V565 E566 L618 ≥ 1 resistance mutation detected at baseline, and all rendered undetectable at C2D1 ≥ 1 resistance mutation detected at baseline and C2D1 N550 V565 E566 L618 Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021)
FGFR2 – RLY-4008 FIH Study: RLY-4008 Showed Radiographic Tumor Regression in FGFR2 Oncogenic Mutations and in FGFR2 Amplifications *Confirmed PR with increased tumor reduction after data cut; ^PR pending confirmation. 1. Based on Company’s review of presented meeting abstracts and published studies to-date. Note: FC, fold change; CN, copy number. Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference Preliminary data as of 09-Sept-2021 * ^ ^ FGFR2 Oncogenic Mutations FGFR2 Amplifications No FDA-approved FGFR targeted therapies for FGFR2 oncogenic mutations or amplifications First known confirmed PR for an FGFR inhibitor for FGFR-mutated breast cancer1 Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021) Patient remains on treatment in C12 at 50 mg QD
FGFR2 – RLY-4008 First-in-Human (FIH) Study Design Orally dosed; BID and QD schedules explored using the Bayesian Optimal Interval Escalation (BOIN) design; Starting dose was 50 mg BID Key Objectives: MTD/RP2D, safety, pharmacokinetics, biomarkers (ctDNA, tumor markers), preliminary anti-tumor activity MTD, maximum tolerated dose; RP2D: recommended phase 2 dose. Unresectable or metastatic solid tumors FGFR2-alterations per local assessment (tumor tissue or blood) Both FGFRi-naïve & FGFRi-treated allowed Part 1: Dose Escalation – Enrolling RP2D Part 2: Dose Expansion – Opened December 2021 FGFR2-fusion+ intrahepatic cholangiocarcinoma with prior FGFRi FGFR2-fusion+, non intrahepatic cholangiocarcinoma with/without prior FGFRi FGFR2-amplified, advanced solid tumors with/without prior FGFRi FGFR2-mutant, advanced solid tumors with/without prior FGFRi FGFR2-fusion+ intrahepatic cholangiocarcinoma without prior FGFRi First patient treated in Sept 2020 70 mg QD dose chosen for part 2 dose expansion
FGFR2 – Highlights from RLY-4008 Interim Clinical Data Disclosure (Oct 2021) Robust inhibition of FGFR2 with promising initial tolerability data Safety and Tolerability Early evidence of tumor regressions across several tumor and alteration types (with 3 out of 6 fusion positive cholangiocarcinoma FGFR-inhibitor naïve patients exhibiting confirmed PRs) Early Efficacy No significant hyperphosphatemia (FGFR1) or diarrhea (FGFR4) observed to-date Selectivity RLY-4008 data support: Implications for Relay Tx Relay Tx’s Dynamo™ platform and approach Relay Tx’s clinical development execution capabilities Ability to achieve rapid proof-of-concept to enable further clinical development RLY-4008 Data Source: RLY-4008 data as presented at 2021 AACR-NCI-EORTC Molecular Targets Conference Preliminary data as of 09-Sept-2021 Data from 2021 AACR-NCI-EORTC Molecule Targets Presentation (October 2021)
PI3Kα Opportunity Is Among the Largest Ever for Precision Oncology Sources: FoundationInsights® database; SEER; Alpelisib – FDA prescribing label 1. Annual incidence of solid tumors with KRAS G12C, PI3K H1047R, PI3K H1047X, PI3K E542X + E545X alterations; 2. Head & Neck Squamous Cell Carcinoma; 3. Clear Cell Ovarian Cancer PI3Kα alterations observed across multiple tumor types – select indications Evolution of PI3K inhibitors Pan-mutant selective drug represents significant clinical opportunity CCOC3 HNSCC2 HER2- Breast Cervical US Patients - Comprehensive Incidence (Annual) 40K 30K 20K 0 10K 50K 60K 70K 80 90 ~58K ~7K ~4K ~600 ~86K KRAS G12C ~58K PI3Kα ~99K H1047X ~9K ~48K E542X, E545X H1047R ~156K (excl. H1047R) US Patients – Solid Tumors Incidence (Annual)1 Pan-PI3K inhibitors: Significant toxicity PI3Kα-predominant inhibitor (alpelisib): PFS benefit with limited TI Pan-mutant selective inhibitor needed Pan-PI3K/mTOR inhibitors: Significant toxicity 2010s 2019 Today First gen H1047X E542X, E545X Solid Tumors (other)
PI3Kα – Existing Inhibitors Establish POC, but Have Limited Therapeutic Window Compound/ Company Stage Mutant Selective Regimen Response Rate % of Patients with Hyperglycemia % of Patients with GI Toxicity % of Patients Discontinued or Dose Reduced Alpelisib Approved No Monotherapy (Dose Escalation) 3% (1/36) 52% (24% Gr3-4) 40% 52% Combo (Fulvestrant) in mBC, CDKi pre-treated 19% mPFS 7.3mo 58% (28% Gr3-4) 60% 83%1 Inavolisib Phase 3 No Monotherapy (Dose Escalation) 20% (4/20) 70% (20% Gr3-4) 40% 30%2 Triplet mBC Combo, no prior CDKi (CDK4/6 + Fulvestrant) 40% (6/15) 61% (23% Gr3-4) 48% 36% Non-Breast Cancer Monotherapy Anecdotal Responses Validate PIK3CA as a Tumor Driver Outside Breast Cancer Compound PI3K Isoform Selectivity Mutant Selective Tumor Types Where Monotherapy Objective Responses In PIK3CAm Patients Have Been Observed (# of Patients) Alpelisib Alpha-Predominant No Cervical (6), Breast (2), Endometrial (2), Colorectal (2), GIST (2), Head & Neck (1) Inavolisib Alpha-Predominant No Breast (4) Taselisib Alpha, Delta, Gamma No Head & Neck (4), Breast (3), Endometrial (2), Cervical (2), CCA (2), CRC (1), Pancreatic (2), Salivary Gland (1) CYH33 Alpha-Predominant No Clear-Cell Ovarian (1), Other Ovarian (1), Breast (1), CRC (1), Gastric (1) Breast Cancer Monotherapy and Combo Data from Leading Competitors Includes dose interruptions in addition to dose reductions and discontinuations Dose reductions only; discontinuations not reported Sources: Alpelisib Monotherapy – Juric et al 2018; Alpelisib Combo – 2021 SABCS Presentation – BYLieve Cohort A; Inavolisib Monotherapy – SABCS 2019 Poster, Inavolisib Combo – SABCS 2020 Poster; Taselisib Monotherapy – Jhaveri et al 2020; CYH33 – ESMO-TAT 2020 Presentation Hyperglycemia is on-target tox from PI3Kα WT
PI3Kα – Relay Tx Has a Unique Understanding of PI3Kα PI3Kα Franchise PI3KαPAN RLY-2608* Pan-mutant selective allosteric inhibitor PI3KαSPECIFIC H1047R-specific allosteric inhibitor PI3KαOTHER Other PI3Kα allosteric programs Relay Tx has a unique understanding of PI3Kα RLY-2608 (pan-mutant selective) is the foundation of our franchise Kinase domain mutation hotspot H1047 Helical domain mutation hotspots E542 and E545 Orthosteric site KRAS experience teaches us pan-mutant coverage is required Similarities between PI3K and KRAS: Clear oncogenic driver Mutations cluster at a few key hotspots Hotspot mutations can occur with multiple different alleles On-target resistance to mutation-specific inhibitors can result in escape via different allele at same site or mutation at another hotspot Examples of on-target resistance mechanisms KRAS G13D KRAS G12V KRAS Y96D KRAS G12C Source: Hata, Helst, & Corcoran et al, Cancer Discovery 2021 *RLY-2608 covers H1047X, E542X, E545X hot spots
PI3Kα – Proprietary Insights Unlock Additional Approaches A differentiated understanding of the structure of PI3Kα and its relationship to function equips Relay Tx to design optimal mutant-selective inhibitors of PI3Kα Designed pan-mutant selective PI3Kα inhibitor (PI3KαPAN) Discovered novel allosteric pocket favored in mutant protein Solved first full-length structures of PI3Kα (mutant and wild-type) Mutant PI3Kα Orthosteric Site
PI3Kα – RLY-2608 Has Shown Mutant and Isoform Biochemical Selectivity Potency (nM) H1047R E542K E545K WT Alpelisib Inavolisib RLY-2608 RLY-2608 has shown biochemical selectivity for mutant over wild type PI3Kα α-mut Potency (nM) β δ Alpelisib RLY-2608 Inavolisib RLY-2608 was inactive on other isoforms γ α-mut β δ γ α-mut β δ γ PI3K Isoforms Mutant vs. WT PI3Kα potency Mutant PI3Kα vs. other isoform potency H1047R E542K E545K WT H1047R E542K E545K WT δ (delta) isoform is an important anti-target for GI toxicity Source: RLY-2608 data as presented in 2021 AACR-NCI-EORTC Molecular Targets Conference poster presentation
PI3Kα – RLY-2608 Is Selective Across the Kinome RLY-2608 inhibited only PI3Kα, with preferential inhibition of mutant Source: RLY-2608 data as presented in 2021 AACR-NCI-EORTC Molecular Targets Conference poster presentation
PI3Kα – In Vivo Tumor Regressions Across Both Mutation Hotspots (Mouse Study) H1047R mutant (HCC1954) (mouse) Source: RLY-2608 data as presented in 2021 AACR-NCI-EORTC Molecular Targets Conference poster presentation 1. This model also carries a second mutation at K567R; 2. HSC2 model; 3. Similar results observed in the same background strain at 1hr timepoint in the MCF7 (E545K) model E545K mutant (MDAMB361) (mouse)1 RLY-2608 achieved active doses with less insulin than orthosteric inhibitors2 Insulin levels after repeat dosing in tumor-bearing mice Consistent results for 1-hour time point3
PI3Kα – RLY-2608 Combines with Standard of Care Therapies to Drive Regressions in ER+/HER2- Breast Cancer Models ST1056 (ER+/HER2-; H1047R) ST986 (ER+/HER2-; E542K) Combination arms with similar tolerability to monotherapy arms RLY-2608 RLY-2608 Fulvestrant and combo Fulvestrant and combo Abemaciclib and combo Abemaciclib and combo Triple combo Triple combo ¼ of fully efficacious monotherapy dose Superior efficacy observed in the triple combination ¼ of fully efficacious monotherapy dose Superior efficacy observed preclinically in the triple combination Source: RLY-2608 data as presented in 2021 SABCS poster presentation
PI3Kα – RLY-2608 Trial Design Part 1: Dose Escalation a. Excludes PIK3CAmut clear cell OvCA, HNSCC, and Cervical cancer patients; b. Double mutation defined as one major PIK3CA mutation (E542X, E545X, H1047X) + ≥1 additional PI3KCA mutation per local assessment; c. Intolerance to PI3K alpha inhibitors is defined as treatment discontinuation due to treatment-related AE (e.g., hyperglycemia, rash, diarrhea, stomatitis) other than severe hypersensitivity reaction and/or life-threatening reactions, such as anaphylaxis and Stevens-Johnson syndrome. Part 2: Dose Expansion MTD/RP2D PIK3CAmut advanced solid tumors PIK3CA double mutant advanced solid tumors b (N=15) PIK3CAmut Clear Cell OvCA (N = 15) PIK3CAmut HNSCC (N = 15) PIK3CAmut Cervical CA (N = 15) Other solid tumors with a PIK3CAmut a (N = 15) RLY-2608 Arm PIK3CAmut, HR+ HER2- advanced / met BC MTD/RP2D PIK3CAmut, HR+, HER2- advanced breast cancer, with NO prior PI3K alpha inhibitor (N = 15) PIK3CAmut, HR+, HER2- advanced breast cancer, intolerant to PI3K alpha inhibitor c (N = 15) RLY-2608 + Fulvestrant Arm First-in-human clinical trial initiated
Challengers – Supporting the Build of Our Dynamo™ Platform Increasing Technical Difficulty Increasing Competition Innovators Challengers Challengers Have Lower Technical Risk Challengers Solve Problems with “Known” Answers Enable higher volume of programs Serve as a data factory and increase experience Our challengers: SHP2 RLY-1971 -- EXPERIMENTATION COMPUTATION The more we do, the better we get
SHP2 – RLY-1971 Is Potent and Selective with Potential for Multiple Therapeutic Uses Potential Patient Populations Key Differentiating Features of RLY-1971 RLY-1971 and GDC-6036 (KRAS G12C) combination trial initiated in July 2021 Projected to be continuous once daily dosing Dosing potential Demonstrated 750pM IC50 inhibition of SHP2 in biochemical assays Potency Chemically distinct from other SHP2 inhibitors Novel chemistry RLY-1971 Discovery Time from hit to development candidate (DC) # of chemical series RLY-1971 (SHP2) Hit DC ~2 years 22 Conventional drug discovery approach Hit DC ~3-5+ years 1-2 Sources: SEER; Foundation Medicine Insights; JAMA Netw Open. 2019;2(5):e192535. doi:10.1001/jamanetworkopen.2019.2535 20 15 10 0 35 5 30 25 NSCLC CRC 2021 U.S. Patients (000’s) EGFR mut. PD-1/PD-L1 ALK fusions KRAS G12C ~31K ~6K Based on annual comprehensive incidence in the US 60 20 120 0 40 80 100 ~103K ~32K 2021 U.S. Patients (000’s) % pts. eligible x % pts. respond to checkpoint inhibitors (US) Solid Tumors
Challengers – Creating a Data Factory The acquisition of our ML-DEL capabilities unlocks our ability to be a data factory Chemical biology insights Deep structural understanding Physics-based simulations AI / ML Dynamo™️ Platform EXPERIMENTATION COMPUTATION ML-DEL 001000001001001001010111001001001001001000100101001001001001001101010110 001110010110001011000100000100100100101010100111 100100100100100010010100 101001110010010010010010001001010010010010010011010100011100101100010110 Large Datasets Insightful Predictions ML Algorithms Data Experimental Validation
Relay Tx – What to Expect Execution focus underpins value creation RLY-2608 (PI3KαPAN) RLY-4008 (FGFR2) To be disclosed in 1H 2022 Next target in pipeline RLY-1971 (SHP2) $617M Cash, cash equivalents and investments as of the end of Q3 2021 $381M Net proceeds from follow-on offering in October 2021 Expansion cohorts open Additional data update expected in 2H 2022 Clinical trial initiated GDC-6036 (KRAS G12C) combo trial initiated in July 2021
